Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Krebs Biochemicals and Industries Limited (KREBSBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, Krebs Biochemicals and Industries Limited (KREBSBIO) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-16.76 Million) by net assets (₹-1.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Krebs Biochemicals and Industries Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Krebs Biochemicals and Industries Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Krebs Biochemicals and Industries Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Krebs Biochemicals and Industries Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Celebrity Fashions Limited
NSE:CELEBRITY
|
0.149x |
|
Lichen China Limited Class A Ordinary Shares
NASDAQ:LICN
|
-0.029x |
|
Geekco Technologies Corp
V:GKO
|
0.288x |
|
Sacgasco Limited
PINK:SGCSF
|
1.421x |
|
Silynxcom Ltd.
NYSE MKT:SYNX
|
-0.329x |
|
Hagag Europe Development ZF Ltd
TA:HGGE
|
-0.086x |
|
NexPoint Hospitality Trust
V:NHT-U
|
-0.173x |
|
Vivic Corp
OTCQB:VIVC
|
0.119x |
Annual Cash Flow Conversion Efficiency for Krebs Biochemicals and Industries Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Krebs Biochemicals and Industries Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹-1.46 Billion | ₹-78.91 Million | 0.054x | +379.21% |
| 2024-03-31 | ₹-1.19 Billion | ₹23.04 Million | -0.019x | -107.78% |
| 2023-03-31 | ₹-994.62 Million | ₹-247.13 Million | 0.248x | +8.38% |
| 2022-03-31 | ₹-750.93 Million | ₹-172.16 Million | 0.229x | -32.78% |
| 2021-03-31 | ₹-427.33 Million | ₹-145.75 Million | 0.341x | -75.98% |
| 2020-03-31 | ₹-249.96 Million | ₹-354.98 Million | 1.420x | +453.62% |
| 2019-03-31 | ₹-142.89 Million | ₹-36.65 Million | 0.257x | -36.19% |
| 2018-03-31 | ₹-177.79 Million | ₹-71.47 Million | 0.402x | +105.30% |
| 2017-03-31 | ₹14.77 Million | ₹-112.03 Million | -7.586x | -546.70% |
| 2016-03-31 | ₹130.14 Million | ₹-152.65 Million | -1.173x | +61.99% |
| 2015-03-31 | ₹293.34 Million | ₹-905.18 Million | -3.086x | -128.22% |
| 2014-03-31 | ₹36.02 Million | ₹393.89 Million | 10.936x | +7105.64% |
| 2013-03-31 | ₹79.48 Million | ₹-12.41 Million | -0.156x | -149.36% |
| 2012-03-31 | ₹231.51 Million | ₹73.21 Million | 0.316x | +362.51% |
| 2011-03-31 | ₹405.89 Million | ₹-48.89 Million | -0.120x | +62.25% |
| 2010-03-31 | ₹486.10 Million | ₹-155.10 Million | -0.319x | -936.28% |
| 2009-03-31 | ₹1.24 Billion | ₹-38.28 Million | -0.031x | -143.94% |
| 2008-03-31 | ₹910.46 Million | ₹-11.49 Million | -0.013x | +87.43% |
| 2007-03-31 | ₹911.90 Million | ₹-91.60 Million | -0.100x | -162.51% |
| 2006-03-31 | ₹884.15 Million | ₹142.09 Million | 0.161x | -- |